A Trinity Life Sciences report found that more pharma product launches were successful in 2023 than the year before. Here are ...
Zacks.com on MSN1d
Eli Lilly Falls More Than 10% in a Month: Buy, Sell or Hold the Stock?One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...
Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent ...
INDIANAPOLIS, Nov. 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from studies of Jaypirca® (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine ...
What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...
MCL can be hard to treat because it is aggressive and usually not curable. Jaypirca offers a new option for people with MCL. With targeted action on cancer cells, Jaypirca helps control the ...
Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback